Incyte CorporationINCY

INCY current price
$82.34+53.48%

Capital at risk.

1W
+8.92%
1M
+25.92%
3M
+31.46%
6M
+42.91%
1Y
+53.48%
MAX
+16.97%
About Incyte Corporation
Ticker
info
INCY
Trading on
info
NASDAQ
ISIN
info
US45337C1027
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Herve Hoppenot
Headquarters
info
1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Employees
info
2,524
Website
info
incyte.com
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
Metrics
BasicAdvanced
Market cap
info
$16.1B
P/E ratio
info
926.44
EPS
info
$0.09
Dividend Yield
info
0.00%
Beta
info
0.71
Forward P/E ratio
info
12.92
EBIDTA
info
$80.5M
Ex dividend date
info
-
Price & volume
Market cap
info
$16.1B
Average daily volume
info
1.9M
90-day return
info
31.46%
30-day return
info
25.92%
7-day return
info
8.92%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
926.44
Forward P/E
info
12.92
PEG ratio
info
0.7
Trailing P/E
info
926.44
Price to sales
info
3.94
Price to book
info
5.07
Earnings
EPS
info
$0.09
EPS estimate (current quarter)
info
$1.07
EPS estimate (next quarter)
info
$1.54
EBITDA
info
$80.5M
Revenues (TTM)
info
$4.08B
Revenues per share (TTM)
info
$18.97
Technicals
Beta
info
0.71
52-week High
info
$83.95
52-week Low
info
$50.35
50-day moving average
info
$67.48
200-day moving average
info
$61.28
Short ratio
info
3.86
Short %
info
6.77%
Management effectiveness
ROE (TTM)
info
0.80%
ROA (TTM)
info
0.12%
Profit margin
info
0.80%
Gross profit margin
info
$1.59B
Operating margin
info
14.96%
Growth
Quarterly earnings growth (YoY)
info
28.90%
Quarterly revenue growth (YoY)
info
23.80%
Share stats
Outstanding Shares
info
193M
Float
info
160M
Insiders %
info
2.05%
Institutions %
info
103.97%
Analyst Insights & forecasts
info

47% Buy

50% Hold

3% Sell

Based on information from 26 analysts.

Average price target

info
$77.34
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$1.06
$1.16
8.62%
Q4 • 23Beat
$0.64
$0.84
23.81%
Q1 • 24Beat
-$1.82
-$1.55
17.42%
Q2 • 24Beat
$1.07
$1.07
-
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$1.04B
$-445M
42.60%
Q2 • 24
$1.14B
$106M
9.36%
Q3 • 24
9.02%
123.94%
121.96%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$4.66B
$1.66B
35.71%
Q2 • 24
$5.01B
$1.84B
36.73%
Q3 • 24
7.52%
10.60%
2.86%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-576M
$214M
$-2B
$-631M
Q2 • 24
$311M
$38.3M
$-32.4M
$293M
Q3 • 24
154.01%
82.10%
98.38%
146.46%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.56

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Incyte Corporation share?
Collapse

Incyte Corporation shares are currently traded for $82.34 per share.

How many shares does Incyte Corporation have?
Collapse

Incyte Corporation currently has 193M shares.

Does Incyte Corporation pay dividends?
Collapse

No, Incyte Corporation doesn't pay dividends.

What is Incyte Corporation 52 week high?
Collapse

Incyte Corporation 52 week high is $83.95.

What is Incyte Corporation 52 week low?
Collapse

Incyte Corporation 52 week low is $50.35.

What is the 200-day moving average of Incyte Corporation?
Collapse

Incyte Corporation 200-day moving average is $61.28.

Who is Incyte Corporation CEO?
Collapse

The CEO of Incyte Corporation is Herve Hoppenot.

How many employees Incyte Corporation has?
Collapse

Incyte Corporation has 2,524 employees.

What is the market cap of Incyte Corporation?
Collapse

The market cap of Incyte Corporation is $16.1B.

What is the P/E of Incyte Corporation?
Collapse

The current P/E of Incyte Corporation is 926.44.

What is the EPS of Incyte Corporation?
Collapse

The EPS of Incyte Corporation is $0.09.

What is the PEG Ratio of Incyte Corporation?
Collapse

The PEG Ration of Incyte Corporation is 0.7.

What do analysts say about Incyte Corporation?
Collapse

According to the analysts Incyte Corporation is considered a hold.